Trevi Therapeutics, Inc.
TRVI
$16.64
-$0.18-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -51.11M | -45.61M | -42.76M | -45.86M | -47.30M |
| Total Depreciation and Amortization | 137.00K | 141.00K | 144.00K | 151.00K | 149.00K |
| Total Amortization of Deferred Charges | 26.00K | 26.00K | 26.00K | -- | -- |
| Total Other Non-Cash Items | 6.68M | 4.93M | 3.99M | 3.91M | 3.35M |
| Change in Net Operating Assets | -8.36M | -4.79M | -3.49M | -2.21M | 1.11M |
| Cash from Operations | -52.63M | -45.30M | -42.09M | -44.01M | -42.68M |
| Capital Expenditure | -238.00K | -114.00K | -12.00K | -19.00K | -7.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -176.38M | -67.08M | -94.10M | -87.35M | -28.76M |
| Cash from Investing | -176.62M | -67.19M | -94.11M | -87.37M | -28.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -11.00K | -42.00K | -74.00K |
| Issuance of Common Stock | 166.43M | 112.39M | 121.11M | 172.32M | 176.21M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 61.00K | 138.00K | -84.00K | -84.00K | -590.00K |
| Cash from Financing | 166.49M | 112.53M | 121.01M | 172.20M | 175.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.76M | 38.00K | -15.18M | 40.82M | 104.10M |